Skip to content

Study · In vitro (cells) · 2024

8 results

Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.

Hou Y, Fan Y, Cheng Y, Peng X, Shan C, Yang Y

International heart journal15 May 2024Cited by 3 (Europe PMC)

PMID38749748 (opens in a new tab)DOI10.1536/ihj.23-576 (opens in a new tab)PepBankPUB-38749748
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In an LPS-induced atherosclerosis cell model, liraglutide at 10, 50 and 100 nmol/L markedly suppressed expression of inflammatory factors after 24 hours.

    In plain wordsIn cells, liraglutide strongly reduced inflammation markers after 24 hours.

    Peptide
    Liraglutide
    Outcome
    DecreaseExpression of inflammatory factors
    Study

    n: not reported in source

    LPS-induced atherosclerosis cell model with co-cultured endothelial cells
    Comparator
    Dulaglutide 100 nmol/L
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10, 50 and 100 nmol/L · 24 hoursAs given in this study.

    Source sentences

    Summary
    The results verify that 10/50/100 nmol/L liraglutide and 100 nmol/L dulaglutide markedly suppressed the expression of inflammatory factors in LPS-induced atherosclerosis after 24 and 72 hours, respectively.
    1 context sentence
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
  2. 02LabIn vitro (cells)Mechanism

    In an LPS-induced atherosclerosis cell model, liraglutide promoted polarization of M1 macrophages toward the M2 phenotype.

    In plain wordsIn cells, liraglutide shifted inflammatory macrophages toward an anti-inflammatory type.

    Peptide
    Liraglutide
    Outcome
    IncreaseM1 to M2 macrophage polarization
    Study

    n: not reported in source

    LPS-induced atherosclerosis cell model with co-cultured endothelial cells
    Comparator
    Dulaglutide 100 nmol/L
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, they promoted the polarization of M1 macrophages toward the M2 phenotype and improved the function of co-cultured endothelial cells.
    1 context sentence
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
  3. 03LabIn vitro (cells)Mechanism

    In an LPS-induced atherosclerosis cell model, liraglutide improved the function of co-cultured endothelial cells.

    In plain wordsIn cells, liraglutide improved the function of blood vessel lining cells grown with the macrophages.

    Peptide
    Liraglutide
    Outcome
    IncreaseFunction of co-cultured endothelial cells
    Study

    n: not reported in source

    LPS-induced atherosclerosis cell model with co-cultured endothelial cells
    Comparator
    Dulaglutide 100 nmol/L
    Outcome group
    Lung injury and fibrosis · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    improved the function of co-cultured endothelial cells.
    1 context sentence
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
  4. 04LabIn vitro (cells)Mechanism

    In the cell model, dulaglutide needed a longer intervention to show an effect, and liraglutide showed a superior dose-dependent effect.

    In plain wordsIn cells, liraglutide worked in a clearer dose-dependent way than dulaglutide, which needed longer exposure to show an effect.

    Peptide
    Liraglutide
    Outcome
    Not applicableDose dependence of anti-inflammatory effect versus dulaglutide
    Study

    n: not reported in source

    LPS-induced atherosclerosis cell model with co-cultured endothelial cells
    Comparator
    Dulaglutide 100 nmol/L
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The difference between the two resided in the extended intervention duration required to observe the effect of dulaglutide, and liraglutide demonstrated a superior dose-dependent manner.
    1 context sentence
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
  5. 05LabIn vitro (cells)Mechanism

    In the cell model of atherosclerotic inflammation, dulaglutide suppressed inflammatory factor expression after exposure.

    In plain wordsIn cells, dulaglutide reduced inflammatory factor expression.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInflammatory factor expression
    Study

    n: not reported in source

    LPS-induced atherosclerotic inflammation and co-cultured endothelial cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    100 nmol/L · 72 hoursAs given in this study.

    Source sentences

    Summary
    The results verify that 10/50/100 nmol/L liraglutide and 100 nmol/L dulaglutide markedly suppressed the expression of inflammatory factors in LPS-induced atherosclerosis after 24 and 72 hours, respectively.
    2 context sentences
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
    Summary · context
    The expression of inflammation markers was examined by immunofluorescence, Western blotting, and real-time PCR.
  6. 06LabIn vitro (cells)Mechanism

    In the cell model, dulaglutide promoted macrophage polarization from the M1 to M2 phenotype.

    In plain wordsIn cells, dulaglutide promoted macrophage polarization toward the M2 phenotype.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMacrophage polarization
    Study

    n: not reported in source

    LPS-induced atherosclerotic inflammation and co-cultured endothelial cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    100 nmol/L · 72 hoursAs given in this study.

    Source sentences

    Summary
    Moreover, they promoted the polarization of M1 macrophages toward the M2 phenotype and improved the function of co-cultured endothelial cells.
    2 context sentences
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
    Summary · context
    The expression of inflammation markers was examined by immunofluorescence, Western blotting, and real-time PCR.
  7. 07LabIn vitro (cells)Efficacy outcome

    In co-cultured endothelial cells, dulaglutide improved cell function.

    In plain wordsIn cells, dulaglutide improved endothelial cell function.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseEndothelial cell function
    Study

    n: not reported in source

    LPS-induced atherosclerotic inflammation and co-cultured endothelial cells
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    100 nmol/L · 72 hoursAs given in this study.

    Source sentences

    Summary
    Moreover, they promoted the polarization of M1 macrophages toward the M2 phenotype and improved the function of co-cultured endothelial cells.
    2 context sentences
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
    Summary · context
    The expression of inflammation markers was examined by immunofluorescence, Western blotting, and real-time PCR.
  8. 08LabIn vitro (cells)Other

    In the cell model, dulaglutide required a longer intervention than liraglutide before its effect appeared.

    In plain wordsIn cells, dulaglutide required a longer exposure than liraglutide before its effect appeared.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTime required for effect
    Study

    n: not reported in source

    LPS-induced atherosclerotic inflammation and co-cultured endothelial cells
    Comparator
    Liraglutide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    100 nmol/L · 72 hoursAs given in this study.

    Source sentences

    Summary
    The difference between the two resided in the extended intervention duration required to observe the effect of dulaglutide, and liraglutide demonstrated a superior dose-dependent manner.
    3 context sentences
    Summary · context
    The results verify that 10/50/100 nmol/L liraglutide and 100 nmol/L dulaglutide markedly suppressed the expression of inflammatory factors in LPS-induced atherosclerosis after 24 and 72 hours, respectively.
    Summary · context
    This study aimed to compare the similarities and differences between liraglutide and dulaglutide in terms of inhibiting atherosclerotic inflammation and improving co-cultured endothelial cell function.
    Summary · context
    The expression of inflammation markers was examined by immunofluorescence, Western blotting, and real-time PCR.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.